leisure time -WSS

leisure time

author：comprehensive 2025-10-02 21:06:10 - browse：4177

AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July. Gonzalez had previously said he would depart when AbbVie had a plan in place to move on from its best-selling drug, Humira, which is now facing competition from cheaper biosimilars.

He will be replaced by Chief Operating Officer Robert Michael, who, like Gonzalez, is a longtime AbbVie executive. Gonzalez, 70, will become executive chairman of the board of directors.

Gonzalez should be a sobering reminder to the drug industry’s critics of how resilient a CEO’s reputation can be. Because while he has been a subject of nearly constant criticism for AbbVie’s handling of Humira and the patents protecting it, investors are likely to remember him fondly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： The creative science of coining drug names

focus

WSS

Crowdfunding for medical bills sidesteps core problem, author says

JPM pitch from hospitals? Revenue streams outside of patient care

Boston Scientific acquires urology company Axonics for $3.7 billion

Crowdfunding for medical bills sidesteps core problem, author says

Welsh Carson private equity firm escapes from FTC antitrust case

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

knowledge

leisure time

focus

Continuity nursing helped my family in our darkest PICU moments

Physician assistants need a new name. Here's what it should be

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

As demand for Covid shots wanes, Moderna seeks its next success

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Medicare details structure of new drug price negotiation program

Is it ever OK for doctors to lie to their patients?

Virginia high school admissions case could be legal follow

Lawmakers grill UnitedHealth CEO on Change cyberattack

knowledge

Allen Institute goes after foundational questions, CEO Costa says

Has Bernie Sanders reached the limit of his pharma bullying effort?

Profiling embryos to choose those with higher IQs is almost a reality

Chemotherapy before breast cancer surgery might fuel metastasis

Welsh Carson private equity firm escapes from FTC antitrust case

AI for drug discovery: Experts on separating hype from reality

focus

knowledge

leisure time

hotspot